A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Public ClinicalTrials.gov record NCT06452277. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations
Study identification
- NCT ID
- NCT06452277
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 444 participants
Conditions and interventions
Conditions
Interventions
- Carboplatin Drug
- Cisplatin Drug
- Pembrolizumab Drug
- Pemetrexed Drug
- Sevabertinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 27, 2024
- Primary completion
- Oct 27, 2027
- Completion
- Jun 26, 2029
- Last update posted
- May 17, 2026
2024 – 2029
United States locations
- U.S. sites
- 27
- U.S. states
- 14
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Patty & George Hoag Cancer Center | Newport Beach | California | 92663 | Withdrawn |
| UC San Diego Health - Moores Cancer Center | San Diego | California | 92037 | Recruiting |
| UCSF Bakar Precision Cancer Medicine Building - Thoracic Surgery and Oncology | San Francisco | California | 94158 | Recruiting |
| UCLA Health Santa Monica Cancer Care | Santa Monica | California | 90404 | Recruiting |
| The Oncology Institute of Hope and Innovation - Fort Lauderdale 17th Street | Fort Lauderdale | Florida | 33316 | Recruiting |
| Memorial Cancer Institute at Miramar | Miramar | Florida | 33029 | Recruiting |
| AdventHealth Cancer Institute Orlando | Orlando | Florida | 32804 | Recruiting |
| Moffitt Cancer Center - Magnolia Campus | Tampa | Florida | 33612 | Recruiting |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Not yet recruiting |
| Piedmont Healthcare - Atlanta | Atlanta | Georgia | 30318 | Recruiting |
| John B. Amos Cancer Center | Columbus | Georgia | 31904 | Recruiting |
| University of Illinois Hospital - Outpatient Cancer Care Center | Chicago | Illinois | 60612 | Recruiting |
| The University of Chicago Medical Center - Hyde Park - Hematology & Oncology | Chicago | Illinois | 60637 | Recruiting |
| UM Greenebaum Comprehensive Cancer Center | Baltimore | Maryland | 21201 | Recruiting |
| UMass Memorial Medical Center - University Campus - Hematology/Oncology | Worcester | Massachusetts | 01655-0002 | Withdrawn |
| Profound Research -OMG - TriAtria Cancer Center | Farmington Hills | Michigan | 48334 | Recruiting |
| Profound Research - OMG - Royal Oak Cancer Center | Royal Oak | Michigan | 48073 | Recruiting |
| M Health Fairview Masonic Cancer Clinic - Clinics and Surgery Center | Minneapolis | Minnesota | 55455 | Recruiting |
| R.J. Zuckerberg Cancer Center | New Hyde Park | New York | 11042 | Withdrawn |
| UC Medical Center - Oncology | Cincinnati | Ohio | 45219 | Recruiting |
| Taylor Cancer Research Center | Maumee | Ohio | 43537 | Recruiting |
| Providence Cancer Institute - Franz Clinic | Portland | Oregon | 97213 | Recruiting |
| Providence Oncology and Hematology Care Clinic Westside | Portland | Oregon | 97225 | Recruiting |
| Allegheny General Hospital | Pittsburgh | Pennsylvania | 15212 | Recruiting |
| University Hospital Simmons Cancer Center Lung/Head Neck Clinic | Dallas | Texas | 75235 | Withdrawn |
| The University of Texas MD Anderson Cancer Center - Texas Medical Center | Houston | Texas | 77030 | Recruiting |
| VCU Health Ambulatory Care Center - Cardiology | Richmond | Virginia | 23298 | Withdrawn |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 255 non-U.S. sites.
Recently updated Advanced Non-small Cell Lung Cancer trials
Other public records listing Advanced Non-small Cell Lung Cancer. Sorted by last update posted; newest first. Not a recommendation.
- NCT05785767: A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
- NCT06731413: Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC) Recruiting
- NCT07222566: Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Recruiting
- NCT04613596: Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 Recruiting
- NCT05099172: First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) Active, not recruiting
- NCT02133196: T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06452277, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 17, 2026 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06452277 live on ClinicalTrials.gov.